ReviewPaediatric drugs2017
Pharmacotherapy for Seizures in Neonates with Hypoxic Ischemic Encephalopathy.
Review in Paediatric drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Anti-seizure medications for neonates with seizures.The Cochrane database of systematic reviews · 2023Pooled it
- Efficacy of antiepileptic drugs in neonatal seizures: a systematic review protocol.BMJ paediatrics open · 2020Pooled it
- Article
- An epigenetic perspective on neonatal encephalopathy with suspected hypoxic ischaemic encephalopathy.Clinical epigenetics · 2025Review
- Treatment considerations for the management of neonatal onset seizures.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025Article
- Continuous electroencephalography in the intensive care unit: A critical review and position statement from an Australian and New Zealand perspective.Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine · 2023Article
- Emerging therapies and management for neonatal encephalopathy-controversies and current approaches.Journal of perinatology : official journal of the California Perinatal Association · 2021Review
- What is the Best Predictor of Phenobarbital Pharmacokinetics to Use for Initial Dosing in Neonates?Pharmaceutics · 2021Review
- Iatrogenic Neonatal Coma.Indian journal of pediatrics · 2020Article
- Article
- "Neonatal seizure: how reliable is its diagnosis and treatment? A mini review of previous knowledge".Iranian journal of child neurology · 2020Review
- Lidocaine as treatment for neonatal seizures: Evaluation of previously developed population pharmacokinetic models and dosing regimen.British journal of clinical pharmacology · 2020Article
- Blood Pressure Profiles in Infants With Hypoxic Ischemic Encephalopathy (HIE), Response to Dopamine, and Association With Brain Injury.Frontiers in pediatrics · 2020Article
- Neonatal seizures: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data.Vaccine · 2019Review
- Transient ischemia facilitates neuronal chloride accumulation and severity of seizures.Annals of clinical and translational neurology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Seizures are common in neonates with moderate and severe hypoxic ischemic encephalopathy (HIE) and are associated with worse outcomes, independent of HIE severity. In contrast to adults and older children, no new drugs have been licensed for treatment of neonatal seizures over the last 50 years, because of a lack of controlled clinical trials. Hence, many antiseizure medications licensed in older children and adults are used off-label for neonatal seizure, which is associated with potential risks of adverse effects during a period when the brain is particularly vulnerable. Phenobarbital is worldwide the first-line drug and is considered standard of care, although there is a limited evidence base for its efficacy. Second-line agents include phenytoin, benzodiazepines, levetiracetam, and lidocaine. These drugs are discussed in more detail along with two emerging drugs (bumetanide and topiramate). More safety, pharmacokinetic, and efficacy data are needed from well-designed clinical trials to develop safe and effective antiseizure regimes for the treatment of neonatal seizures in HIE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.